Datopotamab Deruxtecan
AstraZeneca and Daiichi Reach Key Milestone in Breast Cancer ADC Trial, Paving Way to Challenge Gilead
Anika Sharma
AstraZeneca and Daiichi Sankyo are making a strategic move to challenge Gilead Sciences’ position in the breast cancer arena. They ...
Datopotamab Deruxtecan + Imfinzi Transform First-Line NSCLC Treatment in TROPION-Lung04 Trial
Anika Sharma
The TROPION-Lung04 Phase Ib trial has unveiled highly promising results. The trial showcases the potential of datopotamab deruxtecan (Dato-DXd), in ...
DATOPOTAMAB DERUXTECAN MEETS DUAL PRIMARY ENDPOINT IN TROPION-LUNG01 PHASE III TRIAL FOR ADVANCED NON-SMALL CELL LUNG CANCER
SG Tylor
On July 3, 2023, AstraZeneca presented encouraging top-line results from the TROPION-Lung01 Phase III trial that demonstrated the positive efficacy ...
